CLINICAL & EXPERIMENTAL METASTASIS
Scope & Guideline
Exploring the Frontiers of Cancer Metastasis
Introduction
Aims and Scopes
- Metastatic Mechanisms and Biology:
Research into the biological underpinnings of metastasis, including cellular and molecular mechanisms that facilitate cancer spread. This includes studies on epithelial-mesenchymal transition (EMT), genetic alterations, and tumor microenvironment interactions. - Therapeutic Strategies and Innovations:
Exploration of novel therapeutic approaches aimed at preventing or treating metastasis, such as targeted therapies, immunotherapies, and combination treatments. This encompasses clinical trials and preclinical studies. - Diagnostic Techniques and Biomarkers:
Development and evaluation of diagnostic tools and biomarkers for early detection of metastasis, including imaging techniques, circulating tumor cells (CTCs), and liquid biopsies. - Clinical Outcomes and Patient Management:
Investigation of clinical outcomes related to metastatic cancer, including treatment responses, prognostic factors, and patient quality of life. This also includes analyses of treatment regimens and their efficacy. - Translational Research and Preclinical Models:
Utilization of translational research approaches and preclinical models to bridge laboratory findings with clinical applications, thereby enhancing the understanding of metastasis in a real-world context.
Trending and Emerging
- Immunotherapy and Immune Checkpoint Inhibition:
There is a significant increase in studies exploring the role of immunotherapy and immune checkpoint inhibitors in treating metastatic cancers, reflecting a broader trend in oncology toward harnessing the immune system. - Liquid Biopsy and Circulating Tumor Cells (CTCs):
Research focusing on liquid biopsies and CTCs has gained momentum, emphasizing their potential for non-invasive monitoring of metastatic disease and treatment response. - Targeted Therapies and Personalized Medicine:
A notable trend is the exploration of targeted therapies that are tailored to the specific genetic and molecular profiles of tumors, which has become increasingly important in the management of metastatic cancers. - Tumor Microenvironment and Metastatic Niche:
The investigation of the tumor microenvironment and its influence on metastatic behavior is emerging as a critical area of research, highlighting the complex interactions that drive metastasis. - Preclinical Models and Translational Research:
There is a growing emphasis on the use of advanced preclinical models and translational research to better predict clinical outcomes and improve therapeutic strategies against metastasis.
Declining or Waning
- Basic Research on Non-Metastatic Tumor Biology:
There appears to be a waning interest in research focused solely on the biology of primary tumors without a direct connection to metastatic processes, as the field shifts toward understanding the complexities of metastasis. - Conventional Chemotherapy Approaches:
Studies centered on traditional chemotherapy regimens for metastatic cancer are less frequent, as there is a growing emphasis on personalized medicine and targeted therapies that offer more tailored treatment options. - Single-Agent Therapies:
Research dedicated to single-agent therapies is declining, as current trends favor combination therapies that leverage synergistic effects to combat metastasis more effectively. - Descriptive Studies without Translational Insight:
There has been a noticeable decrease in purely descriptive studies that do not provide translational insights or therapeutic implications, indicating a shift towards research that directly informs clinical practice.
Similar Journals
Cancers
Empowering discovery in oncology and cancer treatment.Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.
Molecular & Cellular Oncology
Connecting researchers to the forefront of oncology.Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.
ONCOGENE
Advancing Cancer Research Through Innovative InsightsONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.
CANCER BIOLOGY & THERAPY
Connecting knowledge and innovation in cancer therapy.CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.
CANCER RESEARCH
Connecting researchers to transformative cancer studies.Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.
INTERNATIONAL JOURNAL OF CANCER
Exploring the frontiers of cancer science and treatment.INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.
ONCOLOGY RESEARCH
Connecting Ideas, Advancing OncologyONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.
Journal of Bone Oncology
Unlocking Innovations in Bone Cancer TreatmentJournal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.
Annual Review of Cancer Biology
Transforming Insights into Cancer BiologyAnnual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Transforming cancer research into clinical solutions.The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.